The authors performed a randomized clinical trial, the proPSMA trial, to compare the diagnostic performances of PSMA-PET/CT vs. conventional imaging (both contrast-enhanced CT and bone scintigraphy) in patients with a high and very high risk of PCa. The gene discussed is FOLH1; the disease is posterior cortical atrophy.